NovaBay Pharmaceuticals Inc (NBY)
0.0788
0.00 (0.00%)
USD |
NYAM |
Apr 26, 16:00
0.0781
0.00 (0.00%)
After-Hours: 20:00
NovaBay Pharmaceuticals Research and Development Expense (Quarterly): 0.004M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.004M |
| September 30, 2023 | 0.011M |
| June 30, 2023 | 0.027M |
| March 31, 2023 | 0.026M |
| December 31, 2022 | 0.066M |
| September 30, 2022 | 0.041M |
| June 30, 2022 | 0.04M |
| March 31, 2022 | 0.028M |
| December 31, 2021 | 0.008M |
| September 30, 2021 | 0.01M |
| June 30, 2021 | 0.021M |
| March 31, 2021 | 0.005M |
| December 31, 2020 | 0.036M |
| September 30, 2020 | 0.125M |
| June 30, 2020 | 0.115M |
| March 31, 2020 | 0.009M |
| December 31, 2019 | 0.018M |
| September 30, 2019 | 0.049M |
| June 30, 2019 | 0.032M |
| March 31, 2019 | 0.085M |
| December 31, 2018 | 0.107M |
| September 30, 2018 | 0.045M |
| June 30, 2018 | 0.061M |
| March 31, 2018 | 0.046M |
| December 31, 2017 | 0.146M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.132M |
| June 30, 2017 | 0.07M |
| March 31, 2017 | 0.062M |
| December 31, 2016 | 0.156M |
| September 30, 2016 | 0.004M |
| June 30, 2016 | 0.278M |
| March 31, 2016 | 0.933M |
| December 31, 2015 | 1.225M |
| September 30, 2015 | 1.563M |
| June 30, 2015 | 1.357M |
| March 31, 2015 | 1.583M |
| December 31, 2014 | 2.405M |
| September 30, 2014 | 2.312M |
| June 30, 2014 | 2.238M |
| March 31, 2014 | 2.528M |
| December 31, 2013 | 4.037M |
| September 30, 2013 | 2.513M |
| June 30, 2013 | 2.937M |
| March 31, 2013 | 2.925M |
| December 31, 2012 | 2.119M |
| September 30, 2012 | 2.514M |
| June 30, 2012 | 2.378M |
| March 31, 2012 | 2.264M |
| December 31, 2011 | 2.199M |
| September 30, 2011 | 2.023M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.004M
Minimum
Dec 2023
0.125M
Maximum
Sep 2020
0.0353M
Average
0.027M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| Eyenovia Inc | 4.065M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |
| Oragenics Inc | 11.04M |